Form 4: Biogen Executive Nicole Murphy Reports Stock Transactions
SEC Form 4
Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, reports the acquisition and disposal of Biogen common stock and restricted stock units.
Summary
- Nicole Murphy, a Biogen executive, filed a Form 4 detailing changes in beneficial ownership of Biogen stock.
- On February 7, 2025, Murphy acquired 2,102 and 1,940 shares of common stock through the vesting of restricted stock units.
- Also on February 7, 2025, Murphy disposed of 620 and 603 shares of common stock at a price of $141.35.
- Following these transactions, Murphy directly owns 12,453.3741 shares of Biogen common stock.
- Murphy also directly owns 3,880 restricted stock units.
- A new grant of 14,050 restricted stock units was made on February 6, 2025, vesting in three equal yearly installments beginning on February 6, 2026.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing primarily reports routine stock transactions. The acquisition of shares through vesting is mildly positive, while the disposal is mildly negative, balancing out overall.
Positives
- The vesting of restricted stock units indicates a continued investment in the company by the executive.
Negatives
- The disposal of shares, while potentially for tax purposes, could be interpreted negatively by some investors.
Risks
- Executive stock transactions can sometimes be misinterpreted by the market, leading to short-term price volatility.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are regularly monitored by investors for insights into management's perspective on the company's performance and future prospects.
Comparison to Industry Standards
- Executive compensation packages, including restricted stock units, are standard practice in the biotechnology industry.
- Companies like Amgen (AMGN) and Gilead Sciences (GILD) also utilize stock-based compensation to align executive interests with shareholder value.
- The vesting schedules and terms of these grants are generally comparable across the industry, with variations based on company-specific performance metrics and strategic goals.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the potential for price fluctuations, but the overall impact is likely to be minimal.
Key Dates
| Date | Description |
|---|---|
| 02/08/2023 | Grant date for restricted stock units vesting in three equal annual installments commencing one year after this date. |
| 02/07/2024 | Grant date for restricted stock units vesting in three equal annual installments commencing one year after this date. |
| 02/06/2025 | Grant date for 14,050 restricted stock units vesting in three equal yearly installments beginning on the first anniversary of this date. |
| 02/06/2025 | Date of earliest transaction reported. |
| 02/07/2025 | Date of common stock transactions (acquisition and disposal). |
| 02/10/2025 | Date of Form 4 filing. |
| 02/06/2026 | First vesting date for restricted stock units granted on February 6, 2025. |
| 02/08/2026 | Expiration date for restricted stock units vesting in three equal annual installments commencing one year after the grant date of 02/08/2023. |
| 02/07/2027 | Expiration date for restricted stock units vesting in three equal annual installments commencing one year after the grant date of 02/07/2024. |
| 02/06/2028 | Expiration date for 14,050 restricted stock units granted on February 6, 2025. |
Keywords
Biogen, BIIB, stock, restricted stock units, insider trading, Form 4, Nicole Murphy, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.